Soybean compounds make radiation treatment of lung cancer tumors more effective, reveals study.
A team led by Gilda Hillman, Ph.D., professor of radiation oncology at Wayne State University's School of Medicine and the Barbara Ann Karmanos Cancer Institute, had shown previously that soy isoflavones, a natural, nontoxic component of soybeans, increases the ability of radiation to kill cancer cells in prostate tumors.
It blocks DNA repair mechanisms and molecular survival pathways, which are turned on by the cancer cells to survive the damage radiation causes.
During the past year, Hillman's team achieved similar results in non-small cell lung cancer cells in vitro.
Hillman emphasized that soy supplements alone are not a substitute for conventional cancer treatment, and that doses of soy isoflavones must be medically administered in combination with conventional cancer treatments to have the desired effects.
"Preliminary studies indicate that soy could cause radioprotection," she said.
"It is important to show what is happening in the lung tissue."
She said that the next step is to evaluate the effects of soy isoflavones in mouse lung tumor models to determine the conditions that will maximize the tumor-killing and normal tissue-protecting effects during radiation therapy.
"If we succeed in addressing preclinical issues in the mouse lung cancer model showing the benefits of this combined treatment, we could design clinical protocols for non-small cell lung cancer to improve the radiotherapy of lung cancer."
"We also could improve the secondary effects of radiation, for example, improving the level of breathing in the lungs."
Once protocols are developed, the clinicians can begin using soy isoflavones combined with radiation therapy in humans, a process they believe will yield both therapeutic and economic benefits.
"In contrast to drugs, soy is very, very safe."
"It's also readily available, and it's cheap," she added.
The study has been published in the journal Radiotherapy and Oncology.